Live Analyst Rating Changes 25942 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jason Cassorla
GUGG

Jason Cassorla

Guggenheim
Wall Street Analyst
★★★☆☆
#1638
on 13Foresight · ranked by our own returns
67%
Success Rate
+12.3%
Average Return
22 of 33 calls profitable · +44.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 67% of Jason Cassorla's ratings turned a profit when each position was held for 1 year — averaging +12.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

50 Buy 13 Hold 0 Sell
Jason's Stock Coverage 17 ratings · 2026-08-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CTEV
Claritev
 Aug 07, 2026 BUY Strong Buy
-3.6% avg upside
8 analysts
$44.00
24.70% Upside
 +9.0% ·
ARDT
Ardent Health Partners, Inc.
 Aug 05, 2026 BUY Buy
+27.1% avg upside
16 analysts
$14.00
27.34% Upside
 -2.4% ·
BTSG
BrightSpring Health Services, Inc.
 Jul 31, 2026 BUY Strong Buy
+11.0% avg upside
20 analysts
$81.00
36.41% Upside
 +2.1% ·
CI
Cigna
 Jul 30, 2026 BUY Strong Buy
+24.2% avg upside
29 analysts
$361.00
28.75% Upside
 -4.3% ·
ACHC
Acadia Healthcare
 Jul 29, 2026 BUY Strong Buy
+48.8% avg upside
17 analysts
$39.00
39.61% Upside
 +12.7% ·
HUM
Humana
 Jul 29, 2026 BUY Buy
+10.0% avg upside
34 analysts
$471.00
22.87% Upside
 +6.5% ·
UHS
Universal Health
 Jul 28, 2026 BUY Buy
+13.2% avg upside
22 analysts
$189.00
7.97% Upside
 +2.3% ·
CNC
Centene
 Jul 28, 2026 HOLD Buy
+10.1% avg upside
29 analysts
 — +1.5% ·
THC
Tenet Healthcare
 Jul 27, 2026 BUY Strong Buy
-12.2% avg upside
27 analysts
$283.00
4.45% Upside
 +11.0% ·
MOH
Molina Healthcare
 Jul 23, 2026 HOLD Hold
+15.9% avg upside
26 analysts
 — +1.7% ·
ELV
Elevance Health
 Jul 15, 2026 BUY Strong Buy
+13.0% avg upside
33 analysts
$455.00
13.34% Upside
 +2.0% ·
CYH
Community Health
 Apr 22, 2026 HOLD Sell
+39.4% avg upside
18 analysts
 — +10.7% ·
HCA
HCA Healthcare
 Jan 27, 2026 HOLD Buy
-1.1% avg upside
36 analysts
 — -17.6% ·
PACS
PACS Group Inc
 Sep 11, 2024 BUY Strong Buy
+11.3% avg upside
9 analysts
$45.00
1.65% Upside
 -75.7% ·
SGRY
Surgery Partners
 Aug 07, 2024 BUY Strong Buy
+57.3% avg upside
18 analysts
$36.00
152.24% Upside
 -18.8% ·
CLOV
Clover Health Investments
 May 08, 2024 HOLD Hold
-13.2% avg upside
9 analysts
$1.00
76.39% Downside
 +330.5% ·
INNV
InnovAge Holding
 Feb 27, 2024 HOLD Sell
-34.1% avg upside
12 analysts
$6.50
41.44% Downside
 -33.5% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jason Cassorla — Frequently Asked Questions
How accurate are Jason Cassorla's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Jason's ratings were profitable over a one-year hold, with an average return of +12.3% per rating, or +44.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Jason ranked on 13Foresight?
Jason Cassorla is currently ranked #1638 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jason cover?
Jason most recently has ratings on CTEV, ARDT, BTSG, CI, ACHC, HUM, UHS, CNC, THC, MOH, ELV, CYH and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.